Over the last three decades, trends in endometrial cancer incidence have been heterogeneous in various developed areas of the world. In North America, endometrial cancer incidence tended to rise from the early 1960's to the mid 1970's, but flattened off or declined from the early 1980's onwards . Conversely, incidence was still increasing in the early 1980's in Denmark (Ewertz & Jensen, 1984) and in most other cancer registration areas in Europe (Parazzini et al.-, 1991) , although some reversal of trends has been observed over more recent periods in Britain (Villard & Murphy, 1990) , East Germany (Nischan & Ebeling, 1991) and Sweden (Persson et al., 1990) in women before age 55. This has been discussed in terms of a favourable impact of oral contraceptives on endometrial cancer rates for these younger cohorts of women (Villard & Murphy, 1990; Nischan & Ebeling, 1991; Persson et al., 1990) .
To provide further documentation on the descriptive epidemiology of endometrial cancer, we present here incidence and survival data from the Cancer Registry of the Canton of Vaud, Switzerland. In this cancer registration area, incidence rates were among the highest on a European scale (Levi et al., 1989) .
The data were abstracted from the Vaud Cancer Registry file (Levi, 1987) (Levi et al., 1992) . (1974-78, 1979-83 and 1984-88) . The fall in rates was substantial at younger age (i.e., under 50 years, particularly over the last calendar quinquennium) and in middle age (from 50 to 59 years), but no clear pattern of trends was apparent above age 60. Thus, there are two main findings emerging from this analysis of endometrial cancer trends in the Swiss Canton of Vaud: a decline in incidence, and some improvement (or, in any case, no evidence of worsening) in survival. Trends in survival data are important in order to understand and interpret changes in incidence, since endometrial cancers related to oestrogen replacement treatment have a better prognosis (Robboy & Bradley, 1979) , and in the United States a substantial decline in incidence following the fall in oestrogen use has been followed by a worsening in survival rates (Anonymous, 1991) .
Following this line of reasoning, changes in pattern of oestrogen replacement use are unlikely to totally explain the declines in endometrial cancer incidence. In the late 1980's, ever use of oestrogen replacement treatment was reported by about 20% of women in peri-menopausal age (Levi et al., 1991) . . In a case-control study conducted in the Canton of Vaud, ever use of oral contraceptives was reported by approximately 60% of women below age 50, and 30% of those aged 50 to 59, and, assuming a protection for ever use of 50% (Levi et al., 1991) , this would imply (Bruzzi et al., 1985) an about 20% reduction in incidence under age 60 (i.e., 30% reduction under age 50, and 15% between 50 and 59), whereas rates under age 60 declined by 40%.
There is no reliable information in trends of obesity -the other major established risk factor for endometrial cancer (La Vecchia et al., 1982) -or on the proportion of women with hysterectomy, but it is clear from the data presented that, besides a relevant role of oral contraceptives, and a changed pattern of menopausal replacement treatment use, only a complex of several factors can explain the favourable endometrial cancer trends reported in this Swiss population over the last two decades. 
